Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study

Authors
Category Primary study
JournalFrontiers in Oncology
Year 2023
This article has no abstract
Epistemonikos ID: ffbabca002c95ac9480df4f63eb5a9db56a7fd0e
First added on: Feb 16, 2025